Geron, Kirin, Merix deal

Kirin and Merix will co-develop dendritic cell vaccines with an initial focus on cancer and HIV. The companies will share profits worldwide. Merix will market resulting products in the U.S. and Canada, while Kirin will market the products in Asia. Rights to Europe and elsewhere will be determined jointly. Each company will contribute $45-$65 million during the first three years of the partnership. Kirin also agreed to make an equity investment in Merix and will appoint a member to Merix's board of directors. ...